What does Keros Therapeutics, Inc. do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap…
What is Keros Therapeutics, Inc.'s P/E and P/B ratio?
Keros Therapeutics, Inc. has a P/E ratio of -3.5 and a P/B ratio of 0.86.
What is Keros Therapeutics, Inc.'s debt-to-equity ratio?
Keros Therapeutics, Inc. has a debt-to-equity ratio of 0.06.
How much does Keros Therapeutics, Inc. owe compared with what it owns?
Keros Therapeutics, Inc. owes $0.09 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Keros Therapeutics, Inc.'s Positivity rank?
Keros Therapeutics, Inc. is ranked #2,776 of 6,774 companies globally and #990 of 4,000 in United States on PositoAI, with a Positivity Score of 21,150.
Does Keros Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Keros Therapeutics, Inc..
Where can I read the latest news about Keros Therapeutics, Inc.?
Recent headlines about Keros Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Keros Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Keros Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.